ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: SA-OR39

Pooled Analyses of the Phase 3 Roxadustat Studies: Congestive Heart Failure Hospitalization Rates in Dialysis and Non-Dialysis Patients with Anemia Treated with Roxadustat vs. Comparators

Session Information

Category: Hypertension and CVD

  • 1402 Hypertension and CVD: Clinical, Outcomes, and Trials


  • Provenzano, Robert, Wayne State University, Detroit, Michigan, United States
  • Szczech, Lynda, FibroGen Inc, San Francisco, California, United States
  • Zhong, Ming, FibroGen Inc, San Francisco, California, United States
  • Lai, Bryant, FibroGen Inc, San Francisco, California, United States
  • Leong, Robert, FibroGen Inc, San Francisco, California, United States
  • Little, Dustin J., AstraZeneca, Gaithersburg, Maryland, United States
  • Yu, Kin-Hung Peony, FibroGen Inc, San Francisco, California, United States

Roxadustat is an orally bioavailable hypoxia-inducible factor prolyl hydroxylase inhibitor that stimulates erythropoiesis and improves iron metabolism. Phase 3 roxadustat studies were performed to treat anemia of chronic kidney disease (CKD). Congestive heart failure (CHF), a common comorbidity in CKD, was also analyzed. CHF is associated with a poorer prognosis in CKD patients, with a prevalence that increases with CKD severity; approximately 20% in mild CKD (>65 years) to 40% in patients on hemodialysis.


Safety data were pooled from pivotal phase 3 studies comparing roxadustat to placebo in Stage 3-5 non-dialysis-dependent (NDD) CKD patients, and to epoetin alfa in the overall dialysis-dependent (DD) patients, and subgroup of incident-dialysis (ID-DD) patients. Patients with baseline (BL) moderate to severe CHF were not enrolled. CHF hospitalization events were a component of the MACE-plus endpoints that were adjudicated by a blinded independent committee, and analyzed by a Cox proportional hazards regression model; these analyses were not powered for individual component endpoints.


In the pooled NDD studies, 4270 patients were analyzed (2386 roxadustat; 1884 placebo). BL CHF history was comparable between roxadustat (13.0%) and placebo (13.6%) arms. Using ITT long-term follow-up, the HR (95% CI) of hospitalization for CHF among the NDD pooled population was 0.89 (0.72, 1.12) for roxadustat vs placebo. In the pooled DD studies, 3880 patients were analyzed (1940 roxadustat; 1940 epoetin alfa). BL CHF history was comparable between roxadustat (25.7%) and epoetin alfa (25.3%) arms, and in the incident dialysis (ID-DD) subgroup (≤4 months of dialysis at BL, n=1526) of 26.4 vs 27.0%, respectively. Using on-treatment analysis comparing roxadustat with epoetin alfa in the DD studies, the HR (95% CI) of hospitalized CHF was 0.73 (0.58, 0.94; p=0.013). In the ID-DD subgroup, the HR (95%CI) was 0.77 (0.42, 1.40).


Roxadustat showed a 27% reduction in risk for CHF hospitalization compared to epoetin alfa in the DD population, and a trend based on the point estimates toward reduction of risk compared to placebo in NDD, and to epoetin alfa in ID-DD patients.


  • Commercial Support